Skin Aging
Conditions
Brief summary
The Researchers are trying to study a cosmetic skin care product called human platelet extract (HPE) to see if it can be used as a possible treatment for skin anti-aging and skin rejuvenation. They are trying find out the safety and tolerability of topical HPE after multiple doses of topical administration
Interventions
BIOLOGICALHuman platelet extract (cosmetic product)
A leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors). Applied to face twice daily for 12 weeks.
OTHERVanicream Gentle Facial Cleanser
A mild cleanser specifically formulated for daily facial use. Applied to face twice daily for 12 weeks
OTHEREltaMD UV Daily Broad-Spectrum SPF 40
A daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD UV Daily Broad-Spectrum SPF 40 provides powerful protection against the sun's harmful UV rays, as it hydrates and is gentle enough for post-procedure skin. Powered by hyaluronic acid, this face sunscreen plumps the skin with lightweight moisture, while micronized zinc and octinoxate shield skin from UVA/UVB rays to prevent the visible signs of environmentally caused aging. Applied to face once daily for 12 weeks.
OTHEREltaMD PM Therapy Facial Moisturizer
A fortifying face moisturizer to repair elasticity and vitality. EltaMD PM Therapy Facial Moisturizer restores youthfulness while strengthening the skin's natural moisture barrier. Niacinamide blends with antioxidants to boost the skin color and tone, as it speeds up the skin's repair processes. Rice protein peptides aid in encouraging cell growth, promoting collagen formation and improving elasticity. Applied to face once daily for 12 weeks.
OTHERVanicream Lite Lotion
Lotion to restore and maintain a normal moisture level. Applied to face twice daily for 12 weeks.
Sponsors
Mayo Clinic
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Persons of childbearing potential must have a negative pregnancy test prior to receiving the study product and will agree to use adequate contraception (hormonal or barrier method or abstinence) from the time of screening to a period of 2 years until discontinuation of treatment. Females of childbearing potential are defined as premenopausal and not surgically sterilized, or post-menopausal for fewer than 2 years. A urine pregnancy test will be performed prior to the administration of the study product to confirm negative results. If the urine pregnancy test is positive, the study product will not be administered, and the result will be confirmed by a serum pregnancy test. Urine pregnancy tests will be performed by qualified personnel using kit. Persons becoming pregnant during the study will continue to be monitored for the duration of the study or completion of the pregnancy, whichever is longer. Monitoring will include perinatal and neonatal outcome. Any Serious Adverse Events (SAE) associated with pregnancy will be recorded. * All skin phototypes ≥ grade I of Fitzpatrick's classification. * Mild-to-moderate global face wrinkles and mild-to-moderate global fine lines based on a modified Griffiths' 10-point scale \[3\]. * Fully understanding of the requirements of the study and willingness to comply with the treatment plan, including laboratory tests, diagnostic imaging, and follow-up visits and assessments. * Volunteer willingness to discontinue any other anti-aging topical or parenteral treatments for the duration of the study. * Can provide written informed consent and complete HIPAA documentation after the nature of the study is fully explained and prior to any study-related treatment. * Can provide written informed consent to being photographed for purposes of treatment for medical, scientific purposes.
Exclusion criteria
* Pregnant or nursing, or planning on becoming pregnant during the study period * Subjects who have had an antiaging or aesthetic treatment prior to the study: Botox or Botox-like products, peelings, plastic surgery, resurfacing with Laser, Intense pulsed light (IPL) therapy, threats, radiofrequency treatments, hyaluronic acid treatment, Plasma-Rich Platelets treatment, or any other specific treatments prone to change the skin aspect during the last 6 months * Individuals with a history of any dermatological disease or condition, including but not limited to active atopic dermatitis, psoriasis, eczema, active seasonal allergies, collagen diseases, or skin cancer involving the treated sites within the past 6 months * Cutaneous marks on the experimental area which could interfere with the assessment of skin reactions (pigmentation problems, scar elements, over-developed pilosity, ephelides, and nevi in too great quantity, sunburn, beauty spots, freckles, etc.) * Participants with asymmetric photodamage on dorsal hands due to environmental exposures (i.e., golfing) and/or other skin lesions including burns or scars resulting in significant skin surface variability between dorsal hands * Eczematous reaction still visible, scar, or pigmentary sequelae of previous tests on the experimental area * Allergy to colophony or nickel. * Allergy or reactivity to drugs, food or cosmetic products previously observed, including perfumes or cologne products. * Skin hyper-reactivity. * Forecast of intensive sun, tanning bed use or UV phototherapy during the test period. * Treatment with prescription-strength Vitamin A acid or its derivatives within 3 months before the beginning of the study. * Treatment with topical steroids on the experimental area within 16 days before the study. Study constraints: * No application of products on the experimental area (except the suggested ones), particularly any anti-aging cosmetic products except for sunscreen. * No change in hygiene habits * No application of any cosmetic moisturizing products on the face or any makeup on face and lips, on the day of study evaluations * No change in the way of life or in the physical activity * No change in dietary activities, or any treatment that significantly impacts body weight * No exfoliating treatment on the experimental areas * Description of any treatment undertaken during the study and all eventual deviations
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Wrinkles Area | baseline, 6 weeks | Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess forehead wrinkles using 3D fringe projection which evaluates static wrinkles and measures the difference in fractional area change |
| Change in Redness Area | baseline, 6 weeks | The percentage of participants to experience at least 50% improvement in redness area over baseline. As measured by photodocumentation with the VISIA-CR Generation 5 3D PRIMOS using RBX technology. Redness pixel variation and the cross polarized image were transformed into red images that correlated with hemoglobin absorption/distribution. |
| Change Brown Spot Area | baseline, 6 weeks | Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess overall variation in color values specifically pixel variation across defined cosmetic subunits and how rapidly those colors change spatially within it, producing a score from 0 to 1, where 0 is less melanin or brown color and 1 is more melanin or brown color. Lower scores reflect better outcomes. |
| Change in Luminosity | baseline, 6 weeks | Luminosity (color intensity) is the measure of the light reflected from the skin surface. Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess overall variation in color values specifically pixel variation across defined cosmetic subunits and how rapidly those colors change spatially within it. Lower values reflect dull and/or uneven skin tones. Higher values reflect radiant and/or even-appearing skin tones. |
| Change in Color Evenness | baseline, 6 weeks | Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess overall variation in color values specifically pixel variation across defined cosmetic subunits and how rapidly those colors change spatially within it, producing a score from 0 to 1, where 0 is dull and/or uneven skin tone and 1 is radiant and/or even-appearing skin tone. Higher scores reflect better outcomes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cosmetic Skin Improvement | 12 weeks | Change measured by the self reported Global Aesthetic Improvement Assessment where subjects grade/rate their improvement as Exceptional/very much improved, Moderate/much improved, Slight, No change or Worse. |
| Satisfaction With Topical Cosmetic Treatment | 12 weeks | Number of subjects to self report satisfied or very satisfied with the treatment on the Modified Cosmetic Improvement questionnaire. |
| Recommendation of Topical Cosmetic Treatment | 12 weeks | Number of subjects to self report they would recommend the treatment to a friend on the Modified Cosmetic Improvement questionnaire. |
| Likelihood of Continuing Topical Cosmetic Treatment | 6 weeks | The number of subjects to self report they are very likely to continue treatment on the Modified Cosmetic Improvement questionnaire. |
| Topical Cosmetic Treatment on Self-esteem | 12 weeks | Number of subjects to self report how the cosmetic treatment affected self-esteem positively or negatively on the Modified Cosmetic Improvement questionnaire. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Human Platelet Extract (HPE) Subjects followed a standardized twice daily skin care regimen of applying morning and night for 12 weeks. Morning included Vanicream Gentle Facial Cleanser, human platelet extract, and EltaMD UV Daily Broad-Spectrum SPF 40, or Vanicream Lite Lotion. Evening skin care routine included Vanicream Gentle Facial cleanser, human platelet extract, and EltaMD PM Therapy Facial Moisturizer or Vanicream Lite Lotion.
Human platelet extract is a leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors. Vanicream Gentle Facial Cleanser is a mild cleanser specifically formulated for daily facial use. EltaMD UV Daily Broad-Spectrum SPF 40 is a daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD PM Therapy Facial Moisturizer is a fortifying face moisturizer to repair elasticity and vitality. Vanicream Lite Lotion is a lotion to restore and maintain a normal moisture level. | 56 |
| Total | 56 |
Baseline characteristics
| Characteristic | Human Platelet Extract (HPE) | — |
|---|---|---|
| Age, Continuous | 54 years STANDARD_DEVIATION 11 | — |
| Race and Ethnicity Not Collected | — | — Participants |
| Region of Enrollment United States | 56 participants | — |
| Sex: Female, Male Female | 48 Participants | — |
| Sex: Female, Male Male | 8 Participants | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 56 |
| other Total, other adverse events | 9 / 56 |
| serious Total, serious adverse events | 0 / 56 |
Outcome results
Primary
Change Brown Spot Area
Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess overall variation in color values specifically pixel variation across defined cosmetic subunits and how rapidly those colors change spatially within it, producing a score from 0 to 1, where 0 is less melanin or brown color and 1 is more melanin or brown color. Lower scores reflect better outcomes.
Time frame: baseline, 6 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Human Platelet Extract (HPE) | Change Brown Spot Area | Baseline | 0.097 pixels | Standard Deviation 0.03 |
| Human Platelet Extract (HPE) | Change Brown Spot Area | 6 weeks | 0.093 pixels | Standard Deviation 0.031 |
Primary
Change in Color Evenness
Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess overall variation in color values specifically pixel variation across defined cosmetic subunits and how rapidly those colors change spatially within it, producing a score from 0 to 1, where 0 is dull and/or uneven skin tone and 1 is radiant and/or even-appearing skin tone. Higher scores reflect better outcomes.
Time frame: baseline, 6 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Human Platelet Extract (HPE) | Change in Color Evenness | Baseline | 0.51 pixels | Standard Deviation 0.07 |
| Human Platelet Extract (HPE) | Change in Color Evenness | 6 weeks | 0.54 pixels | Standard Deviation 0.07 |
Primary
Change in Luminosity
Luminosity (color intensity) is the measure of the light reflected from the skin surface. Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess overall variation in color values specifically pixel variation across defined cosmetic subunits and how rapidly those colors change spatially within it. Lower values reflect dull and/or uneven skin tones. Higher values reflect radiant and/or even-appearing skin tones.
Time frame: baseline, 6 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Human Platelet Extract (HPE) | Change in Luminosity | Baseline | 60.29 pixels | Standard Deviation 5.49 |
| Human Platelet Extract (HPE) | Change in Luminosity | 6 weeks | 63.19 pixels | Standard Deviation 5.24 |
Primary
Change in Redness Area
The percentage of participants to experience at least 50% improvement in redness area over baseline. As measured by photodocumentation with the VISIA-CR Generation 5 3D PRIMOS using RBX technology. Redness pixel variation and the cross polarized image were transformed into red images that correlated with hemoglobin absorption/distribution.
Time frame: baseline, 6 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Human Platelet Extract (HPE) | Change in Redness Area | 42 percentage of participants |
Primary
Change in Wrinkles Area
Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess forehead wrinkles using 3D fringe projection which evaluates static wrinkles and measures the difference in fractional area change
Time frame: baseline, 6 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Human Platelet Extract (HPE) | Change in Wrinkles Area | Baseline | 0.08 pixels | Standard Deviation 0.03 |
| Human Platelet Extract (HPE) | Change in Wrinkles Area | 6 weeks | 0.09 pixels | Standard Deviation 0.03 |
Secondary
Cosmetic Skin Improvement
Change measured by the self reported Global Aesthetic Improvement Assessment where subjects grade/rate their improvement as Exceptional/very much improved, Moderate/much improved, Slight, No change or Worse.
Time frame: 12 weeks
Population: Terminated study. Data was not collected nor analyzed
Secondary
Likelihood of Continuing Topical Cosmetic Treatment
The number of subjects to self report they are very likely to continue treatment on the Modified Cosmetic Improvement questionnaire.
Time frame: 6 weeks
Population: One subject did not complete the questionnaire
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Human Platelet Extract (HPE) | Likelihood of Continuing Topical Cosmetic Treatment | 54 Participants |
Secondary
Recommendation of Topical Cosmetic Treatment
Number of subjects to self report they would recommend the treatment to a friend on the Modified Cosmetic Improvement questionnaire.
Time frame: 12 weeks
Population: Terminated study. Data was not collected nor analyzed
Secondary
Satisfaction With Topical Cosmetic Treatment
Number of subjects to self report satisfied or very satisfied with the treatment on the Modified Cosmetic Improvement questionnaire.
Time frame: 12 weeks
Population: Data was not collected nor analyzed
Secondary
Topical Cosmetic Treatment on Self-esteem
Number of subjects to self report how the cosmetic treatment affected self-esteem positively or negatively on the Modified Cosmetic Improvement questionnaire.
Time frame: 12 weeks
Population: Terminated study. Data was not collected nor analyzed